FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza. Teva blocked from launching generic form of Lilly's Evista; also rumored to be eyeballing a purchase of …
Today’s Top Three in Pharma 033109
When placebos outperform CNS drugs - an interesting article on Seeking Alpha. Afinitor - new cancer blockbuster for Novartis? - Novartis AG’s cancer pill Afinitor, approved yesterday by U.S. …
Today’s Top Three in Pharma 033009
AstraZeneca's Crestor reduces risk of blood clots in the veins - A new analysis from the JUPITER study shows that CRESTOR® (rosuvastatin calcium) 20mg significantly cut the risk of venous …
Today’s Top Three in Pharma 032709
Farewell, DNA - the Roche takeover of Genentech is a done deal. What will this do to the culture of both companies, I wonder? DiabetesTV? Forbes explains. Good news for Amylin and Eli Lilly on …
Today’s Top Three in Pharma 032409
Eli Lilly's Symbyax finally approved for depression - Eli Lilly has received approval from the U.S. Food and Drug Administration for use of a combo pill called Symbyax to treat treatment-resistant …
Today’s Top Three in Pharma 020409
Finally! New anti-clotting drug prasugrel (Effient) is given a thumbs up by advisory committee! Great news for Daiichi Sankyo and Eli Lilly. King Pharmaceuticals the latest to announce major layoffs …